Display options
Cite
Li J, Gurnani PK, Roberts KM, et al. The Clinical Impact of Flow Titration on Epoprostenol Delivery via High Flow Nasal Cannula for ICU Patients with Pulmonary Hypertension or Right Ventricular Dysfunction: A Retrospective Cohort Comparison Study. J Clin Med. 2020;9(2)doi: 10.3390/jcm9020464.
Li, J., Gurnani, P. K., Roberts, K. M., Fink, J. B., & Vines, D. (2020). The Clinical Impact of Flow Titration on Epoprostenol Delivery via High Flow Nasal Cannula for ICU Patients with Pulmonary Hypertension or Right Ventricular Dysfunction: A Retrospective Cohort Comparison Study. Journal of clinical medicine, 9(2), . https://doi.org/10.3390/jcm9020464
Li, Jie, et al. "The Clinical Impact of Flow Titration on Epoprostenol Delivery via High Flow Nasal Cannula for ICU Patients with Pulmonary Hypertension or Right Ventricular Dysfunction: A Retrospective Cohort Comparison Study." Journal of clinical medicine vol. 9,2 (2020). doi: https://doi.org/10.3390/jcm9020464
Li J, Gurnani PK, Roberts KM, Fink JB, Vines D. The Clinical Impact of Flow Titration on Epoprostenol Delivery via High Flow Nasal Cannula for ICU Patients with Pulmonary Hypertension or Right Ventricular Dysfunction: A Retrospective Cohort Comparison Study. J Clin Med. 2020 Feb 07;9(2). doi: 10.3390/jcm9020464. PMID: 32046152; PMCID: PMC7074129.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2020 Feb 07;9(2). doi: 10.3390/jcm9020464.

The Clinical Impact of Flow Titration on Epoprostenol Delivery via High Flow Nasal Cannula for ICU Patients with Pulmonary Hypertension or Right Ventricular Dysfunction: A Retrospective Cohort Comparison Study.

Journal of clinical medicine

Jie Li, Payal K Gurnani, Keith M Roberts, James B Fink, David Vines

Affiliations

  1. Department of Cardiopulmonary Sciences, Division of Respiratory Care, Rush University Medical Center, Chicago, IL 60612, USA.
  2. Department of Pharmacy, Rush University Medical Center, Chicago, IL 60612, USA.
  3. Aerogen Pharma Corp, San Mateo, CA 94402, USA.

PMID: 32046152 PMCID: PMC7074129 DOI: 10.3390/jcm9020464

Abstract

(1) Background: inhaled epoprostenol (iEPO) delivered via high-flow nasal cannula (HFNC) has been reported to be effective for pulmonary hypertension and right ventricular dysfunction. In vitro studies have identified HFNC gas flow as a key factor in trans-nasal aerosol delivery efficiency; however, little evidence is available on the clinical impact of flow titration on trans-nasal aerosol delivery. At our institution, iEPO via HFNC was initiated in 2015 and the concept of flow titration during iEPO via HFNC has been gradually accepted and carried out by clinicians in the recent years. (2) Methods: a retrospective review of the electronic medical records for all adult patients who received iEPO via HFNC in a tertiary teaching hospital. Pre- and post- iEPO responses were reported for patients whose HFNC flow was titrated or maintained constant during iEPO delivery. Positive response to iEPO was defined as the reduction of mean pulmonary arterial pressure (mPAP) > 10% for pulmonary hypertension patients or the improvement of oxygenation [pulse oximetry (SpO

Keywords: epoprostenol; flow titration; high-flow nasal cannula; inhalation; pulmonary hypertension

Conflict of interest statement

Dr. Fink is Chief Science Officer for Aerogen Pharma Corp and discloses relationships with Dance Biopharm. Dr. Vines provides consulting to Ohio medical and Teleflex Medical, INC. Other authors have n

References

  1. Curr Pharm Biotechnol. 2017;18(11):877-882 - PubMed
  2. Gen Thorac Cardiovasc Surg. 2017 Mar;65(3):153-159 - PubMed
  3. Lancet. 2016 Apr 30;387(10030):1867-78 - PubMed
  4. ERJ Open Res. 2019 Aug 12;5(3): - PubMed
  5. Pediatr Pulmonol. 2019 Aug;54(8):1319-1325 - PubMed
  6. J Aerosol Med Pulm Drug Deliv. 2019 Dec;32(6):341-351 - PubMed
  7. J Crit Care. 2013 Oct;28(5):844-8 - PubMed
  8. Chest. 2015 Jun;147(6):1510-1522 - PubMed
  9. Chest. 2007 Aug;132(2):410-7 - PubMed
  10. Pharmaceutics. 2019 May 10;11(5): - PubMed
  11. Respir Care. 2017 Feb;62(2):193-198 - PubMed
  12. Ann Pharmacother. 2018 Dec;52(12):1173-1181 - PubMed
  13. Pharmaceutics. 2019 Jun 14;11(6): - PubMed
  14. Ann Pharmacother. 2015 Oct;49(10):1105-12 - PubMed
  15. Respir Care. 2015 Jun;60(6):794-802; discussion 802-5 - PubMed
  16. Ann Pharmacother. 2016 Jan;50(1):22-6 - PubMed
  17. Pediatr Pulmonol. 2019 Jun;54(6):914-921 - PubMed
  18. Respiration. 2019;98(5):401-409 - PubMed
  19. Anaesth Intensive Care. 2011 Nov;39(6):1103-10 - PubMed
  20. Pharmaceutics. 2019 Jul 07;11(7): - PubMed
  21. Pulm Circ. 2013 Jan;3(1):68-73 - PubMed

Publication Types